Rhenman & Partners Asset Management AB Increases Holdings in Kura Oncology, Inc. (NASDAQ:KURA)

Rhenman & Partners Asset Management AB raised its stake in shares of Kura Oncology, Inc. (NASDAQ:KURA - Free Report) by 88.9% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 314,526 shares of the company's stock after purchasing an additional 148,000 shares during the quarter. Rhenman & Partners Asset Management AB owned approximately 0.40% of Kura Oncology worth $2,740,000 at the end of the most recent reporting period.

A number of other hedge funds have also added to or reduced their stakes in the stock. Barclays PLC boosted its stake in shares of Kura Oncology by 104.5% during the 3rd quarter. Barclays PLC now owns 165,484 shares of the company's stock valued at $3,234,000 after purchasing an additional 84,563 shares in the last quarter. SG Americas Securities LLC bought a new stake in Kura Oncology during the 4th quarter valued at approximately $436,000. Moody Aldrich Partners LLC grew its holdings in shares of Kura Oncology by 42.3% during the 4th quarter. Moody Aldrich Partners LLC now owns 143,587 shares of the company's stock worth $1,251,000 after acquiring an additional 42,712 shares during the period. Harbor Capital Advisors Inc. raised its position in shares of Kura Oncology by 4.4% in the 4th quarter. Harbor Capital Advisors Inc. now owns 49,371 shares of the company's stock worth $430,000 after acquiring an additional 2,076 shares in the last quarter. Finally, Jennison Associates LLC purchased a new position in shares of Kura Oncology in the 4th quarter valued at approximately $623,000.

Wall Street Analyst Weigh In

KURA has been the subject of a number of recent research reports. UBS Group lowered their price target on shares of Kura Oncology from $27.00 to $14.00 and set a "buy" rating for the company in a research report on Thursday, March 6th. HC Wainwright reaffirmed a "buy" rating and set a $40.00 price objective on shares of Kura Oncology in a research report on Thursday, February 27th. BTIG Research cut Kura Oncology from a "buy" rating to a "neutral" rating in a research note on Thursday, February 6th. JMP Securities reaffirmed a "market outperform" rating and issued a $28.00 price target on shares of Kura Oncology in a research report on Thursday, February 6th. Finally, Wedbush reissued an "outperform" rating and set a $36.00 price objective on shares of Kura Oncology in a research report on Tuesday. Three equities research analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average price target of $25.50.

Kura Oncology Price Performance

KURA traded down $0.37 on Thursday, hitting $5.61. 635,294 shares of the company's stock traded hands, compared to its average volume of 1,112,322. Kura Oncology, Inc. has a one year low of $5.41 and a one year high of $23.48. The company has a current ratio of 11.47, a quick ratio of 11.47 and a debt-to-equity ratio of 0.02. The firm has a market cap of $452.63 million, a price-to-earnings ratio of -2.37 and a beta of 0.83. The company's 50 day simple moving average is $7.47 and its 200-day simple moving average is $11.06.

Kura Oncology (NASDAQ:KURA - Get Free Report) last announced its quarterly earnings results on Wednesday, February 26th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.65) by $0.43. The company had revenue of $53.88 million during the quarter, compared to the consensus estimate of $57.96 million. As a group, research analysts anticipate that Kura Oncology, Inc. will post -2.44 EPS for the current year.

Insider Activity at Kura Oncology

In other Kura Oncology news, SVP Thomas James Doyle sold 4,949 shares of the firm's stock in a transaction dated Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $38,948.63. Following the completion of the sale, the senior vice president now owns 88,193 shares of the company's stock, valued at $694,078.91. This trade represents a 5.31 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Mollie Leoni sold 4,963 shares of the company's stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $7.87, for a total value of $39,058.81. Following the transaction, the insider now directly owns 88,253 shares in the company, valued at approximately $694,551.11. This represents a 5.32 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 11,729 shares of company stock valued at $92,307. 5.50% of the stock is owned by corporate insiders.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.